Alnylam Pharmace. sell fenjal
Start price
24.06.24
/
50%
€210.70
Target price
24.06.25
-
Performance (%)
8.16%
End price
01.07.24
€227.90
Summary
This prediction ended on 01.07.24 with a price of €227.90. With a performance of 8.16%, the SELL prediction by fenjal for Alnylam Pharmace. was trending in the wrong direction fenjal has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 4.034% | 4.034% | -48.106% |
| iShares Core DAX® | 0,44 % | 5,64 % | 7,81 % |
| iShares Nasdaq 100 | 1,06 % | 0,28 % | 27,24 % |
| iShares Nikkei 225® | 1,77 % | 0,41 % | 49,27 % |
| iShares S&P 500 | 0,37 % | 1,92 % | 22,34 % |
Comments by fenjal for this prediction
In the thread Alnylam Pharmace. diskutieren
Sell Alnylam Pharmace.